

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)



(10) International Publication Number
WO 2024/028483 A1

(51) International Patent Classification:

A61K 38/18 (2006.01) *A61K 47/10* (2017.01)
A61K 9/00 (2006.01) *A61P 25/00* (2006.01)
A61K 47/02 (2006.01) *A61P 27/16* (2006.01)

(21) International Application Number:

PCT/EP2023/071676

(22) International Filing Date:

04 August 2023 (04.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22189067.6 05 August 2022 (05.08.2022) EP

(71) Applicant: **DOMPÉ FARMACEUTICI SPA** [IT/IT]; Via
Santa Lucia 6, 20121 MILANO (IT).

(72) Inventors: **FETONI, Anna Rita**; 0168 Roma (IT).
ARAMINI, Andrea; c/o Dompé Farmaceutici SPA, Via
Campo di Pile, snc, 67100 L'Aquila (IT). **BRANDOLINI,
Laura**; c/o Dompé farmaceutici SPA, Via Campo di
Pile, snc, 67100 L'Aquila (IT). **COCCHIARO, Pasquale**;
80100 Napoli (IT). **ROMEO, Tiziana**; c/o Dompé far-
maceutici SPA, Via Campo di Pile, 67100 L'Aquila (IT).
DETTA, Nicola; c/o Dompé Farmaceutici SPA, Via Pietro
Castellino, 111, 80131 Napoli (IT). **APPARENTE, Lucia**;
Via Campo di Pile, 67100 L'Aquila (IT). **MATTIOLI, Si-
mone**; 67100 L'Aquila (IT). **CATTANI, Franca**; 67100
L'Aquila (IT). **MANTELLI, Flavio**; c/o Dompé Farmaceu-
tici SPA, Via Campo di Pile, snc, 67100 L'Aquila (IT). **AL-
LEGRETTI, Marcello**; c/o Dompé Farmaceutici SPA, Via
Campo di Pile, snc, 67100 L'Aquila (IT).

(74) Agent: **MAURI, Elisabetta Maria Ester**; c/o DOM-
PÉ FARMACEUTICI SPA, Via Santa Lucia 6, 20121
MILANO (IT).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: INTRANASAL ADMINISTRATION OF BDNF FOR THE TREATMENT OF SENSORINEURAL HEARING LOSS

(57) Abstract: The present invention relates to brain derived nerve factor (BDNF) for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said BDNF is administered intranasally to said subject.

WO 2024/028483 A1